RecruitingNot ApplicableNCT06037941

Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma

Breathprinting (E-Nose) Technology to Measure Response to Treatment of Malignant Pleural Mesothelioma (MPM) Through MPM-Specific Volatile Organic Compounds Detected in Exhalates

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

20 participants

Start Date

Sep 8, 2023

Study Type

INTERVENTIONAL

Conditions

Malignant Pleural Mesothelioma

Summary

The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure how people respond to standard treatment for malignant pleural mesothelioma (MPM). The researchers will study how E-Nose breathprints change over time as people receive standard treatment for MPM. They will also look at how changes in people's E-Nose breathprints compare to changes in their standard imaging scans and in biomarkers of MPM in their blood.

Eligibility

Min Age: 30 YearsMax Age: 85 Years

Inclusion Criteria4

Aged 30-85 years
No history of thoracic cancer or extrathoracic cancer potentially involving pleural metastases (i.e., breast, gastric, colon, or pancreas cancer)
Recent diagnosis of MPM
Documented, signed, and dated informed consent, obtained before any procedures, for the proposed research study, and signed standard surgical consent for surgical resection

Exclusion Criteria2

Aged \<30 or \>85 years at the first outpatient visit
History of thoracic or extrathoracic cancer that puts the subject at risk for pleural or pulmonary metastases

Interventions

DIAGNOSTIC_TESTE-Nose testing

At baseline (before any treatment is administered) approximately when the patient is scheduled for a CT of the Chest and/or PET/CT after initiation of any treatment, as medically permissible and at the PI's discretion. A breath sample from each patient will be captured in a cartridge, which will form the basis for the E-Nose analysis, to be performed by study investigators at UCB.

DIAGNOSTIC_TESTResearch blood

Research blood tests will be obtained at baseline and the first three standard of care follow up visits, scheduled by their treating physician along with a CT of the Chest and/or PET/CT1 to determine whether serum biomarkers of MPM.